Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (996)	3/16/1999 9:52:00 AM
From: celeryroot.com	Respond to of 1972

PORTLAND, Ore., March 16 /PRNewswire/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT), the leading manufacturer of jet injection devices for needle-free drug delivery and developer of a continuous ambulatory blood glucose monitoring system, today announced that phase I human trials have begun with Vaxid, a DNA-based vaccine for the treatment of lymphoma using the Biojector 2000(R) jet injector as a delivery system. The study, sponsored by Vical Incorporated (Nasdaq: VICL), is being conducted at the Stanford University Medical Center under the direction of Dr. John Timmerman and Dr. Ronald Levy, the primary investigators. The Biojector 2000(R) is being used in comparison with needle and syringe because other studies suggest that the Biojector 2000(R) may be a more optimal route of delivery for DNA-based vaccines. "Bioject is committed to developing new applications for our portfolio of needle-free jet injection systems," said Jim O'Shea, Bioject's chairman, president and CEO. "We are pleased that our needle-free technology can be used to enhance the delivery of DNA-based vaccines for the treatment of cancer, a promising new alternative for patients." Bioject Medical Technologies develops, manufactures and markets jet injection systems for needle-free subcutaneous and intramuscular injections. The Company's advanced injection management system, the Biojector 2000(R), has received the Seal of Acceptance from the Alliance of Children's Hospitals, Inc. In a joint venture with Elan Corporation, Bioject is developing an ambulatory, continuous blood glucose monitoring system for diabetes patients.